Literature DB >> 15350383

Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy.

Alexander F Burnett1, Afshin Bahador, Charles Amezcua.   

Abstract

BACKGROUND: Hormonal therapy for endometrial cancer is occasionally warranted in the premenopausal woman who is interested in maintaining fertility. Combining progesterone with an agent that eliminates the adipose production of estrogen will theoretically be more effective than progesterone alone. CASES: Two cases of reproductive-aged women with grade 1 endometrial cancer who were treated with medroxyprogesterone acetate and anastrozole daily for 3 and 6 months subsequently reverted to normal endometrium.
CONCLUSION: Progesterone combined with the elimination of adipose production of estrogen may be an effective therapy in well-differentiated endometrial cancer in the obese premenopausal woman.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350383     DOI: 10.1016/j.ygyno.2004.06.004

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.

Authors:  Erica M Stringer; Gini F Fleming
Journal:  Oncol Hematol Rev       Date:  2013

Review 2.  Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Authors:  Jeong-Yeol Park; Joo-Hyun Nam
Journal:  Oncologist       Date:  2015-02-11

3.  Aromatase excess in cancers of breast, endometrium and ovary.

Authors:  Serdar E Bulun; Dong Chen; Meiling Lu; Hong Zhao; Youhong Cheng; Masashi Demura; Bertan Yilmaz; Regina Martin; Hiroki Utsunomiya; Steven Thung; Emily Su; Erica Marsh; Amy Hakim; Ping Yin; Hiroshi Ishikawa; Sanober Amin; Gonca Imir; Bilgin Gurates; Erkut Attar; Scott Reierstad; Joy Innes; Zhihong Lin
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

Review 4.  Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.

Authors:  Erica M Stringer; Gini F Fleming
Journal:  Eur Endocrinol       Date:  2013-03-15

5.  Chromatin composition alterations and the critical role of MeCP2 for epigenetic silencing of progesterone receptor-B gene in endometrial cancers.

Authors:  Yongli Chu; Yanlin Wang; Guanghua Zhang; Haibin Chen; Sean C Dowdy; Yuning Xiong; Fengming Liu; Run Zhang; Jinping Li; Shi-Wen Jiang
Journal:  Cell Mol Life Sci       Date:  2014-02-15       Impact factor: 9.261

6.  Endometrial adenocarcinoma in a 27-year-old woman.

Authors:  Anis Fadhlaoui; Jamel Ben Hassouna; Mohamed Khrouf; Fethi Zhioua; Anis Chaker
Journal:  Clin Med Insights Case Rep       Date:  2010-08-12

7.  A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.

Authors:  Zhibo Zhang; Huifang Huang; Fengzhi Feng; Jinhui Wang; Ninghai Cheng
Journal:  J Gynecol Oncol       Date:  2019-02-26       Impact factor: 4.401

8.  Isolated uterine metastasis of invasive ductal carcinoma.

Authors:  Deniz Arslan; Deniz Tural; Ali Murat Tatlı; Emre Akar; Mükremin Uysal; Gülgün Erdoğan
Journal:  Case Rep Oncol Med       Date:  2013-03-14

9.  Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone.

Authors:  Alli Straubhar; Andrew P Soisson; Mark Dodson; Elise Simons
Journal:  Gynecol Oncol Rep       Date:  2017-05-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.